| Dr Sebastian F Cherian, MD | |
|
6500 Excelsior Blvd, St Louis Park, MN 55426-4702 | |
| (952) 993-5391 | |
| Not Available |
| Full Name | Dr Sebastian F Cherian |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 6500 Excelsior Blvd, St Louis Park, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265419253 | NPI | - | NPPES |
| 537433200 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 44932 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
| Hutchinson Health | Hutchinson, MN | Hospital |
| Olivia Hospital & Clinic | Olivia, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tria Orthopaedic Center Llc | 3173570561 | 367 |
| Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Researchers have identified a new variant form of Guillain-Barré syndrome that is characterised by prominent acute bulbar palsy without neck or limb weakness.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
› Verified 6 days ago
| Entity Name | Park Nicollet Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Researchers have identified a new variant form of Guillain-Barré syndrome that is characterised by prominent acute bulbar palsy without neck or limb weakness.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
› Verified 6 days ago
| Entity Name | Tria Orthopaedic Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518273085 PECOS PAC ID: 3173570561 Enrollment ID: O20110310000999 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Researchers have identified a new variant form of Guillain-Barré syndrome that is characterised by prominent acute bulbar palsy without neck or limb weakness.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sebastian F Cherian, MD 6465 Wayzata Blvd, Ste 315, St Louis Park, MN 55426-1728 Ph: () - | Dr Sebastian F Cherian, MD 6500 Excelsior Blvd, St Louis Park, MN 55426-4702 Ph: (952) 993-5391 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Researchers have identified a new variant form of Guillain-Barré syndrome that is characterised by prominent acute bulbar palsy without neck or limb weakness.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
An inexpensive, routine blood test could hold the key to why some patients with congestive heart failure do well after being discharged from the hospital and why others risk relapse, costly readmission or death within a year, new Johns Hopkins research suggests.
› Verified 6 days ago
Dr. Chung M Lee, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3212 | |
Kenneth B Heithoff, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 5775 Wayzata Boulevard, Suite 190, St Louis Park, MN 55416 Phone: 952-541-1840 Fax: 952-513-6880 | |
Mark E Myers, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5775 Wayzata Blvd, Suite 190, St Louis Park, MN 55416 Phone: 952-525-6328 Fax: 952-513-6880 | |
Dr. Michael T Akin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 959-299-3539 | |
Deborah Steen, Radiology Medicare: Not Enrolled in Medicare Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-993-5391 | |
Paige N Misselt, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 612-385-0911 | |
Thomas J Gilbert Jr., MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5775 Wayzata Boulevard, Suite 190, St Louis Park, MN 55416 Phone: 952-541-1840 Fax: 952-513-6880 |